NCT00203177

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 254 (actual)
• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	rasagiline mesylate	0.5 rasagiline mesylate
DRUG	rasagiline mesylate 1.0 mg	1.0 mg rasagiline mesylate

Timeline

• Start date: 2001-10-01
• Primary completion: 2006-12-01
• First posted: 2005-09-20
• Last updated: 2010-03-09

Locations

8 sites across 2 countries: United States, Canada